Ligand id: 7908

Name: encorafenib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 11
Hydrogen bond donors 3
Rotatable bonds 11
Topological polar surface area 148.51
Molecular weight 539.15
XLogP 2.45
No. Lipinski's rules broken 2

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Phase III clinical trial NCT01909453 (comparing combination of LGX818 plus MEK162 and LGX818 monotherapy versus vemurafenib in BRAF mutant melanoma) is underway (Nov 2014).
Mechanism Of Action and Pharmacodynamic Effects
The RAF/MEK/ERK signaling pathway regulates cellular proliferation and survival. Inhibiting the activation of this pathway results in a decrease in proliferation of tumor cells, especially in cells carrying activating BRAF mutations such as BRAFV600E.